Background: Topical corticosteroids (TCS) are used frequently for various inflammatory skin conditions. The prolonged daily and inappropriate use of TCS may cause adverse effects such as erythema, atrophy, and telangiectasia. Steroid rosacea or addiction is a distinct adverse effect of inappropriate use of TCS. It occurs most commonly in adult women applying mid- or high-potency TCS to the face. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist approved for treatment Moderate-to-Severe Atopic Dermatitis in childhoods and adults. The role of dupilumab injection in steroid-induced rosacea management is rarely discussed. Aim: To document a new case presentation of atopic dermatitis on high potency topical facial steroid addiction for a duration of 4 years in a young female patient who was successful treated with dupilumab injection and withdrawal therapy. Case Report: A 32-year-old female patient with a history of atopic dermatitis presented with a history of worsening pruritic facial rashes for a one-month duration and on high potency TCS (Clobetasol Propionate ointment 0.05%) since 4 years ago with multiple treatments failure of steroidal withdrawal treated successfully in combination with dupilumab injection. Conclusion: Dupilumab injection considers effective and inducing rapid resolution of signs and symptoms of steroid-induced rosacea in patients with a history of atopic dermatitis in combination with withdrawal therapy without a rebound effect.
Dhossche, J., Simpson, E. and Hajar, T. (2017) Topical Corticosteroid Withdrawal in a Pediatric Patient. The Journal of the American Academy of Dermatology Case Reports, 3, 420-421. https://doi.org/10.1016/j.jdcr.2017.06.006
[3]
Fukaya, M., Sato, K., Sato, M., et al. (2014) Topical Steroid Addiction in Atopic Dermatitis. Drug, Healthcare and Patient Safety, 6, 131-138. https://doi.org/10.2147/DHPS.S69201
[4]
Sheary, B. (2016) Topical Corticosteroid Addiction and Withdrawal—An Overview for GPs. Australian Family Physician, 45, 386-388.
[5]
Hajar, T., Leshem, Y.A., Hanifin, J.M., et al. (2015) A Systematic Review of Topical Corticosteroid Withdrawal (‘‘Steroid Addiction’’) in Patients with Atopic Dermatitis and Other Dermatoses. Journal of the American Academy of Dermatology, 72, 541-549. https://doi.org/10.1016/j.jaad.2014.11.024
[6]
Rapaport, M.J. and Lebwohl, M. (2003) Corticosteroid Addiction and Withdrawal in the Atopic: The Red Burning Skin Syndrome. Clinics in Dermatology, 21, 201-214. https://doi.org/10.1016/S0738-081X(02)00365-6
[7]
Di Rosa, M., Radomski, M., Carnuccio, R. and Moncada, S. (1990) Glucocorticoids Inhibit the Induction of Nitric Oxide Synthase in Macrophages. Biochemical and Biophysical Research Communications, 172, 1246-1252. https://doi.org/10.1016/0006-291X(90)91583-E
[8]
Lavker, R.M. and Schechter, N.M. (1985) Cutaneous Mast Cell Depletion Results from Topical Corticosteroid Usage. The Journal of Immunology, 135, 2368-2373.
[9]
Coleman, J.W. (2002) Nitric Oxide: A Regulator of Mast Cell Activation and Mast Cell-Mediated Inflammation. Clinical and Experimental Immunology, 129, 4-10. https://doi.org/10.1046/j.1365-2249.2002.01918.x
[10]
Goldman, D. (2001) Tacrolimus Ointment for the Treatment of Steroid-Induced Rosacea. A Preliminary Report. Journal of the American Academy of Dermatology, 44, 995-998. https://doi.org/10.1067/mjd.2001.114739
[11]
Bhat, Y.J., Manzoor, S. and Qayoom, S. (2011) Steroid-Induced Rosacea: A Clinical Study of 200 Patients. Indian Journal of Dermatology, 56, 30-32. https://doi.org/10.4103/0019-5154.77547
[12]
Igelman, S., Kurta, A.O., Sheikh, U., McWilliams, A., Armbrecht, E., Jackson Cullison, S.R., Siegfried, E., et al. (2020) Off-Label Use of Dupilumab for Pediatric Patients with Atopic Dermatitis: A Multicenter Retrospective Review. Journal of the American Academy of Dermatology, 82, 407-411. https://doi.org/10.1016/j.jaad.2019.10.010
[13]
Gooderham, M.J., Hong, H.C., Eshtiaghi, P. and Papp, K.A. (2018) Dupilumab: A Review of Its Use in the Treatment of Atopic Dermatitis. Journal of the American Academy of Dermatology, 78, S28-S36. https://doi.org/10.1016/j.jaad.2017.12.022
[14]
Arnold, K.A., Treister, A.D. and Lio, P.A. (2018) Dupilumab in the Management of Topical Corticosteroid Withdrawal in Atopic Dermatitis: A Retrospective Case Series. JAAD Case Reports, 4, 860-862. https://doi.org/10.1016/j.jdcr.2018.06.012
[15]
Sneddon, I. (1968) Varicose Ulcers and Use of Topical Corticosteroids. British Medical Journal, 1, 579-580. https://doi.org/10.1136/bmj.1.5591.579-c
